Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This clinical trial is for men and women age 18 and older with metastatic or locally advanced unresectable gastric or gastro-esophageal junction (GEJ) cancer whose tumors have high or intermediate CLDN18.2 expression. 

Key Inclusion / Exclusion Criteria:
  • Histologically confirmed diagnosis of metastatic or locally advanced unresectable gastric or gastroesophageal junction (GEJ) cancer. 
  • Cohort 1A/1B: Disease progression on or after at least 2 prior treatments, including fluoropyrimidine and platinum-containing chemotherapy, and if appropriate, HER2/neu-targeted therapy
  • Cohort 2: No previous systematic treatment (subject may have received neoadjuvant and/or fluorouracil-containing adjuvant chemotherapy as long as it has been completed ≥ 6 months before the first dose of study treatment). Gastric or GEJ tumor is HER2-negative
  • Detailed eligibility reviewed when you contact the study team

This clinical trial is for men and women age 18 and older with B-cell non-follicular indolent non-Hodgkin’s lymphoma. Relapsed and refractory indolent non-Hodgkin’s lymphomas are difficult to treat with poor overall response rate and overall survival. 

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older. 
  • Histologically confirmed diagnosis of B-cell non-follicular indolent non-Hodgkin’s lymphoma, including Waldenstrom’s macroglobulinemia. 
  • Relapsed or refractory after at least one prior treatment regimen, with no limit on prior therapies. 
  • Detailed eligibility reviewed when you contact the study team. 

This clinical trial is for men and women with unresectable glioblastoma or gliosarcoma at first or second recurrence.

Key Inclusion / Exclusion Criteria:
  • Open to men and women age 18 and older
  • Diagnoses with glioblastoma or gliosarcoma at first or second recurrence
  • Participants must have unresectable disease
  • Detailed eligibility will be reviewed when you contact the study team

This is an international, phase 2, open-label, 2-arm, response rate study of talazoparib (also known as MDV3800, BMN 673), a poly(ADP-ribose) polymerase (PARP) inhibitor in development for treatment of men with metastatic castration-resistant prostate cancer (CRPC) who previously received t

Key Inclusion / Exclusion Criteria:

Age 18 and older. 
Have metastatic castration-resistant prostate cancer
ECOG performance status of 0 to 2 
Detailed eligibility reviewed when you contact the study team. 

    

The purpose of this research study is to compare the effects of the investigational study drugs, PF-06651600 and PF-06700841, with placebo to find out which is better for treating UC. 

Key Inclusion / Exclusion Criteria:

- Men and women 18 Years to 70 Years (Adult, Senior).
- Diagnosis of ulcerative colitis for greater than/equal to 4 months.
- Moderate to severe active ulcerative colitis.
- Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC. 

Exclusion Criteria: 
- Pregnant or breastfeeding
- Clinical findings suggestive of Crohn's Disease 
- History of bowel surgery within 6 months 

    

Currently, patients receiving a transplanted kidney are required to take life-long immunosuppressive medications to prevent rejection of the transplanted kidney. These medications carry substantial side effects.

Key Inclusion / Exclusion Criteria:

Inclusion

  • Planned recipient of a first kidney allograft from an HLA-matched, living related donor.
  • Age greater than or equal to 18 and less than or equal to 65 years at the time of providing informed consent.
  • Single solid organ recipient (kidney only).
  • ABO compatibility with donor
  • Able and willing to fully comply with all study procedures and restrictions.

Exclusion 

  • Underlying kidney disease with a high risk of disease recurrence in the transplanted kidney
  • History of HUS, atypical HUS, or TTP.
  • Is taking immunosuppressive therapy [eg, glucocorticoids, cyclosporine, mycophenolate, tumor necrosis factor (TNF) inhibitors] for multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, or other acute or chronic condition.
  • Tests confirmed positive for HIV-1/2, human T-cell lymphotropic virus (HTLV)-I/II, West Nile Virus, HBV, HCV ,T. cruzi, or syphilis. Epstein-Barr Virus (EBV)- positive donors will be excluded if the prospective transplant recipient is EBV naïve. 
  • History of infection with Zika virus (ZIKV) in the past 6 months

This clinical trial is for men and women with advanced urothelial cancer. The purpose of this study is to compare the effects of an investigational drug called erdafitinib to those of docetaxel or vinflunine (chemotherapy) and of pembrolizumab (immunotherapy).

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older 
  • Urothelial cancer with specific gene mutations 
  • One previous treatment for metastatic disease (disease which has spread to other parts of the body) 
  • Detailed eligibility reviewed when you contact the study team 

This clinical trial is for men and women who have been diagnosed with NonAlcoholic Steatohepatitis (NASH) and liver fibrosis (damaged/scarred liver tissue). Due to NASH, the liver is swollen and damaged because of a buildup of fat in the liver.

Key Inclusion / Exclusion Criteria:
  • Men and women who are 18 years of age and older
  • Must be diagnosed with NASH and liver scarring
  • Detailed eligibility reviewed when you contact the study team

The purpose of this study is to compare the benefits and side effects of ABL001 versus bosutinib in subjects with chronic myelogenous leukemia (CML). CML is characterized by an abnormal chromosome called the 'Philadelphia chromosome'.

Key Inclusion / Exclusion Criteria:
  • Subject must be 18 or older 
  • Subject has diagnosis of CML-CP 
  • Subject has prior treatment with a minimum of 2 prior tyrosine kinase inhibitors 
  • Subject has failed treatment with a minimum of 2 prior tyrosine kinase inhibitors 
  • Detailed eligibility will be reviewed when you contact the study team 

This clinical trial is for males and females with veno-occlusive disease who are scheduled to undergo allogeneic or autologous hematopoietic stem cell transplant (HSCT) and are at high risk or very high risk of developing veno-occlusive disease (VOD). The medicines that are rec

Key Inclusion / Exclusion Criteria:

   - Males and females age 18 through 65
   - Patient must be scheduled to undergo allogeneic or autologous hematopoietic stem cell transplant (HSCT) 
   - Detailed eligibility will be reviewed when you contact the study team.

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.